|
The PATH from Data to Action: Key Findings from the Population Assessment of Tobacco and Health (PATH) Study to Inform FDA’s Regulatory Activities
 A collage image of cups with barcodes, a scientist looking in microscope, virus, and bottle of medication.
Title: The PATH from Data to Action: Key Findings from the Population Assessment of Tobacco and Health (PATH) Study to Inform FDA’s Regulatory Activities
Date: January 9, 2025
Time: 12:00 p.m. - 1:00 p.m.
Webcast
Speaker:
Yu-Ching Cheng, Ph.D.
Supervisory Epidemiologist
Division of Research and Knowledge Integration
Office of Science
Center for Tobacco Products
About the Speaker:
Dr. Yu-Ching Cheng is a Supervisory Epidemiologist of the Population Assessment of Tobacco and Health (PATH) Branch in the Division of Research and Knowledge Integration (DRKI), Office of Science (OS), Center for Tobacco Products (CTP) at the Food and Drug Administration (FDA). The PATH Branch supports the PATH Study, a large, national, longitudinal cohort study on tobacco use and health conducted in collaboration with the National Institute on Drug Abuse, National Institutes of Health. In her current role, she leads a team of epidemiologists, statisticians, and health scientists responsible for data analysis, research coordination and dissemination and day-to-day management of the PATH Study. Prior to joining FDA in 2014, she was an Assistant Professor at the University of Maryland, Baltimore, and a scientist at the Baltimore Veteran Affairs Medical Center with a research background in genetic and cardiovascular epidemiology. Dr. Cheng received her Ph.D. in Epidemiology from the Johns Hopkins Bloomberg School of Public Health in 2008.
About the Presentation:
The Population Assessment of Tobacco and Health (PATH) Study, a national, longitudinal cohort study of tobacco use and health in the United States, is one of the first large tobacco research efforts undertaken by FDA Center for Tobacco Products (CTP) and National Institute of Health (NIH) after Congress gave FDA authority to regulate tobacco products in 2009. This presentation will share an overview and history of the PATH Study, evolution of the study design made over time in response to important changes in tobacco marketplace and regulatory environment and highlight how its designs and findings can inform tobacco regulatory science and public health.
FDA Grand Rounds | FDA
|
